[go: up one dir, main page]

CY1110266T1 - Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης - Google Patents

Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης

Info

Publication number
CY1110266T1
CY1110266T1 CY20091100068T CY091100068T CY1110266T1 CY 1110266 T1 CY1110266 T1 CY 1110266T1 CY 20091100068 T CY20091100068 T CY 20091100068T CY 091100068 T CY091100068 T CY 091100068T CY 1110266 T1 CY1110266 T1 CY 1110266T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
hiv
heterocyclic compounds
bicyclic heterocyclic
hiv integration
Prior art date
Application number
CY20091100068T
Other languages
English (en)
Inventor
B Narasimhulu Naidu
Jacques Banville
Francis Beaulieu
Timothy P Connolly
Mark R Krystal
John D Matiskella
Carl Ouellet
Serge Plamondon
Roger Remillard
Margaret E Sorenson
Yasutsugu Ueda
Michael A Walker
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1110266T1 publication Critical patent/CY1110266T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση περιλαμβάνει σειρά κυκλικών δικυκλικών ενώσεων πυριμιδινόνης του τύπου I οι οποίες αναστέλλουν την HIV ιντεγκράση και εμποδίζουν την ιική ολοκλήρωση στο ανθρώπινο DNA. Η δράση αυτή καθιστά τις ενώσεις χρήσιμες στην αντιμετώπιση της HIV μόλυνσης και του AIDS. Η εφεύρεση επίσης περιλαμβάνει φαρμακευτικές συνθέσεις και μεθόδους για τη θεραπεία ατόμων μολυσμένων με HIV.
CY20091100068T 2004-05-28 2009-01-19 Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης CY1110266T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57551304P 2004-05-28 2004-05-28
US60337104P 2004-08-20 2004-08-20
US11/126,891 US7176196B2 (en) 2004-05-28 2005-05-11 Bicyclic heterocycles as HIV integrase inhibitors
EP05750075A EP1749011B1 (en) 2004-05-28 2005-05-12 Bicyclic heterocycles as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
CY1110266T1 true CY1110266T1 (el) 2015-01-14

Family

ID=35456854

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100068T CY1110266T1 (el) 2004-05-28 2009-01-19 Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης

Country Status (26)

Country Link
US (2) US7176196B2 (el)
EP (1) EP1749011B1 (el)
JP (1) JP4874959B2 (el)
KR (1) KR101097623B1 (el)
AR (1) AR049124A1 (el)
AT (1) ATE412656T1 (el)
AU (1) AU2005250356C1 (el)
BR (1) BRPI0511623A (el)
CA (1) CA2568356C (el)
CY (1) CY1110266T1 (el)
DE (1) DE602005010690D1 (el)
DK (1) DK1749011T3 (el)
ES (1) ES2315875T3 (el)
HR (1) HRP20090005T3 (el)
IL (1) IL179455A (el)
MX (1) MXPA06013835A (el)
NO (1) NO20065879L (el)
NZ (1) NZ551282A (el)
PE (1) PE20060242A1 (el)
PL (1) PL1749011T3 (el)
PT (1) PT1749011E (el)
RS (1) RS50700B (el)
RU (1) RU2381228C2 (el)
SI (1) SI1749011T1 (el)
TW (1) TWI366567B (el)
WO (1) WO2005118593A1 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
JP5116660B2 (ja) * 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007064502A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Forms of n-[(4-fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2007143446A1 (en) * 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2009000661A (es) * 2006-07-19 2009-03-27 Univ Georgia Res Found Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion.
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009120841A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
SG181524A1 (en) 2009-12-07 2012-07-30 Univ Georgia Pyridinone hydroxycyclopentyl carboxamides: hiv integrase inhibitors with therapeutic applications
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013111118A2 (en) * 2012-01-26 2013-08-01 Cro Consulting Limited Agents for treating neurodegenerative disorders
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
SI2997033T1 (en) 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
EP3008044B1 (en) 2013-06-13 2018-11-21 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
HK1221648A1 (zh) 2013-09-27 2017-06-09 Merck Sharp & Dohme Corp. 用作hiv整合酶抑制劑的取代喹嗪衍生物
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
US10544155B2 (en) 2015-12-15 2020-01-28 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as HIV integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
KR20190086017A (ko) 2016-12-02 2019-07-19 머크 샤프 앤드 돔 코포레이션 Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
WO2021050555A1 (en) * 2019-09-10 2021-03-18 X-Chem, Inc. Compositions and uses thereof
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
SI1441735T1 (sl) 2001-10-26 2006-06-30 Angeletti P Ist Richerche Bio N-substituirani hidroksipirimidinon-karboksamidniinhibitorji HIV-integraze
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
WO2004002406A2 (en) 2002-06-26 2004-01-08 Bristol-Myers Squibb Company Bicyclic pyrimidinones as coagulation cascade inhibitors
AU2003292437A1 (en) 2002-12-27 2004-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido(1,2-a)pyrimidines and related compounds useful as hiv integrase inhibitors
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
JP5116660B2 (ja) 2005-03-31 2013-01-09 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Ｈｉｖインテグラーゼ阻害剤

Also Published As

Publication number Publication date
NZ551282A (en) 2009-05-31
EP1749011A1 (en) 2007-02-07
RS50700B (sr) 2010-06-30
ATE412656T1 (de) 2008-11-15
PT1749011E (pt) 2008-11-27
US20060276466A1 (en) 2006-12-07
CA2568356A1 (en) 2005-12-15
AU2005250356C1 (en) 2011-10-06
US20050267105A1 (en) 2005-12-01
JP4874959B2 (ja) 2012-02-15
CA2568356C (en) 2012-07-03
ES2315875T3 (es) 2009-04-01
DK1749011T3 (da) 2009-02-16
NO20065879L (no) 2007-02-20
IL179455A0 (en) 2007-05-15
AU2005250356B2 (en) 2011-03-17
SI1749011T1 (sl) 2009-08-31
KR20070039502A (ko) 2007-04-12
PL1749011T3 (pl) 2009-04-30
RU2381228C2 (ru) 2010-02-10
TWI366567B (en) 2012-06-21
US7511037B2 (en) 2009-03-31
AR049124A1 (es) 2006-06-28
RU2006146970A (ru) 2008-07-10
AU2005250356A1 (en) 2005-12-15
BRPI0511623A (pt) 2008-03-11
TW200600503A (en) 2006-01-01
EP1749011B1 (en) 2008-10-29
MXPA06013835A (es) 2007-02-02
HK1107343A1 (en) 2008-04-03
JP2008501018A (ja) 2008-01-17
DE602005010690D1 (de) 2008-12-11
US7176196B2 (en) 2007-02-13
PE20060242A1 (es) 2006-03-31
HRP20090005T3 (hr) 2009-02-28
KR101097623B1 (ko) 2011-12-22
WO2005118593A1 (en) 2005-12-15
IL179455A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
CY1110266T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της hiv ιντεγκρασης
CY1110665T1 (el) Αναστολεις hiv ιντεγκρασης
NO20082135L (no) HIV integrase inhibitorer
NO20065443L (no) HIV-Integraseinhibitorer: Sykliske pyrimidinonforbindelser
NO20080797L (no) Bicykliske heterocykler som HIV Integrase inhibitorer
WO2008002959A3 (en) Hiv integrase inhibitors
CY1126771T1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
CY1109219T1 (el) Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
CY1113103T1 (el) Φωσφονικα νουκλεοσιδιων και αναλογα εξ αυτων για την αγωγη των λοιμωξεων-hpv
WO2004096128A3 (en) Hiv integrase inhibitors
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
CY1106476T1 (el) Υποκατεστημενες διυδροκιναζολινες με αντι-ιικες ιδιοτητες
NO20083585L (no) Hetero-bisykliske antivirale forbindelser
WO2007059125A3 (en) Hiv integrase inhibitors
CY1107069T1 (el) Χρηση των αναστολεων της cox-2 σαν ανοσοδιεγερτες στη θεραπεια του hiv ή του aids
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
ATE539155T1 (de) Targets und zusammensetzungen zur therapeutischen intervention bei hiv-infektion
NO20083583L (no) Heterosykliske antivirale forbindelser
SE0302304D0 (sv) Novel compounds
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель